<DOC>
	<DOC>NCT02019355</DOC>
	<brief_summary>The main purpose of this study is to determine the effectiveness of a new combination therapy for actinic keratosis. This study investigates a new indication for an FDA-approved topical medication, calcipotriol, for treatment of actinic keratosis, including how well it works and how safe it is when used in combination with the standard of care medication (5-fluorouracil) for the skin condition.</brief_summary>
	<brief_title>Actinic Keratosis Study</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis, Actinic</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Petrolatum</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Age of at least 50 years Presence of four to fifteen clinically typical, visible, and discrete actinic keratoses in 25 cm2 on any of the four anatomical sites: scalp, face, right upper extremity and left upper extremity Ability and willingness of the patient to participate in the study (Informed consent is obtained) Treatment area is within 5 cm of an incompletely healed wound or a suspected basalcell or squamouscell carcinoma Treatment area contained hypertrophic and hyperkeratotic lesions, cutaneous horns, or lesions that had not responded to repeated cryotherapy Recent (within a month) use of medications that could interfere with evaluation of the treatment area (e.g., topical medications, artificial tanners, immunosuppressive medications, immunomodulating agents, cytotoxic drugs, ultraviolet B phototherapy, other therapies for actinic keratoses, or oral retinoids) Premenopausal Women (to avoid any risk of pregnancy) History of hypercalcemia or clinical evidence of vitamin D toxicity</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>